Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

December 28, 2024

Primary Completion Date

December 28, 2024

Study Completion Date

December 28, 2025

Conditions

Kidney Diseases

Interventions

DRUG

Dapagliflozin (DAPA)

adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months

Trial Locations (1)

faculty of pharmacy (girls )ALAzhar university, Cairo

All Listed Sponsors

lead

Al-Azhar University

OTHER

NCT06759077 - Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life | Biotech Hunter | Biotech Hunter